Teneobio, Inc.

19 patents currently held · Updated Nov 14, 2026

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Oct 2037

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Jul 16 to 30, 2027 · next Jul 16
1 fee due Aug 20, 2027
The maintenance fee for Multispecific Heavy Chain Antibodies Binding to CD22 and CD3 (US 11,905,326) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
1 fee due Oct 30, 2027
The maintenance fee for Anti-Bcma Heavy Chain-Only Antibodies (US 11,970,540) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

3 of the patents on this record were granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 11,505,606	CD3 Binding Antibodies In force Term ends Oct 29, 2037 · High confidence	In force	Term ends Oct 29, 2037	High confidence
US 11,434,299	Anti-Bcma Heavy Chain-Only Antibodies In force Term ends Dec 21, 2037 · High confidence	In force	Term ends Dec 21, 2037	High confidence
US 12,570,717	Anti-B-Cell Maturation Antigen Chimeric Antigen Receptors with Human Domains In force Term ends Jun 28, 2038 · Low confidence	In force	Term ends Jun 28, 2038	Low confidence
US 11,427,642	Anti-Bcma Heavy Chain-Only Antibodies In force Term ends Oct 8, 2038 · High confidence	In force	Term ends Oct 8, 2038	High confidence
US 12,371,505	Anti-Bcma Heavy Chain-Only Antibodies In force Term ends Dec 16, 2038 · High confidence	In force	Term ends Dec 16, 2038	High confidence
US 11,873,336	Heavy Chain Antibodies Binding to CD22 In force Term ends Dec 21, 2038 · High confidence	In force	Term ends Dec 21, 2038	High confidence
US 12,495,776	Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies In force Term ends May 8, 2039 · High confidence	In force	Term ends May 8, 2039	High confidence
US 11,613,572	CD3 binding antibodies In force Term ends May 10, 2039 · From the USPTO record	In force	Term ends May 10, 2039	From the USPTO record
US 11,970,540	Anti-Bcma Heavy Chain-Only Antibodies In force Term ends Mar 8, 2040 · High confidence	In force	Term ends Mar 8, 2040	High confidence
US 11,905,326	Multispecific Heavy Chain Antibodies Binding to CD22 and CD3 In force Ends no later than Dec 2, 2040 · Medium confidence	In force	Ends no later than Dec 2, 2040	Medium confidence

10 of 19 patents shown.

Pro members see all 19.

Pro members: see all 19 patents

Also on record, not counted in the 19: 2 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

13 pending · 7 abandoned · 4 no status recorded

List them